IROQUOIS CAPITAL ISSUES STATEMENT IN RESPONSE TO RECENT ACTIONS BY THE PHARMACYTE BIOTECH BOARD OF DIRECTORS
NEW YORK, July 5, 2022 /PRNewswire/ -- Iroquois Capital Management, LLC , one of the largest stockholders of PharmaCyte Biotech, Inc. with beneficial ownership of approximately 6.3% of the...
Source: marketscreener.com